Featured Story | By Annalee Armstrong Eli Lilly's neuroscience team has moved quickly since Aduhelm's June approval to get their own therapy, donanemab, to an accelerated approval filing with the FDA by the end of the year. And the Big Pharma is hoping to beat their competitor to the punch with proof their drug actually slows progression of the disease. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Merck KGaA has found a home for its PAM inhibitor M2698. Three years after wrapping up a phase 1 clinical trial, Merck has offloaded the candidate to a French biotech that plans to start phase 2 solid tumor and lymphoma studies in the second half of next year. read more By Annalee Armstrong Moderna is donating an ultra-rare disease mRNA therapeutic to the Institute for Life Changing Medicines, the nonprofit founded by the late Tachi Yamada, M.D., to find therapies for devastating genetic diseases. read more By Kyle LaHucik HilleVax secured a $135 million crossover investment two months after being spun out of Takeda to focus on developing the Big Pharma's norovirus vaccine candidate, which had been little talked about for the past few years. read more By Kyle LaHucik Pfizer didn't want to fully buy out AM-Pharma after the Dutch biotech failed to meet the primary endpoint in a phase 2 study of patients with sepsis-associated acute kidney injury in 2018. But Kyowa Kirin sees the light at the end of the tunnel and is willing to dish out up to $289 million for the rights to the drug hopeful in Japan. read more By Kyle LaHucik With the COVID-19 pandemic showing no signs of ending anytime soon and a White House ready to funnel billions into preparing for future infectious disease outbreaks, the Bill & Melinda Gates Foundation is investing $35 million in Exscientia for just that. read more By Ben Adams Catabasis Pharmaceuticals has culled staffers, axed pipeline meds and endured some major trial flops. Now, it’s looking to hit the reset button with a new name and focus. read more By Nick Paul Taylor Another month, another Insilico Medicine partnership. After disclosing a series of collaborations over the summer, Insilico has now taken the lid off a new partnership with Huadong Medicine focused on undruggable cancer targets. read more By Kyle LaHucik Replicate Bioscience emerged from stealth with $40 million to bring four programs into the clinic. The biotech is using self-replicating RNA technology to go after cancer and immune disorders and plans to enter the clinic in the second half of 2022. read more By Emmy Lucas EnteroBiotix has rounded up $21.5 million in a series A financing to advance a pipeline of drugs targeting the microbiome, which is believed to play a role in overall health. read more By Angus Liu Sanofi has yet to wrap up its $3.2 billion acquisition of mRNA specialist Translate Bio, but the French pharma is already reaching out to its wallet. This time, it's making a play in general medicines. read more By Kyle LaHucik Decentralized clinical trials company Medrio partnered with biometrics clinical research organization PHASTAR to use electronic patient-reported outcomes data to provide insight on patient compliance and burden. read more By Heather Landi,Garrison Wells Equum Medical pulled in $20 million to build out acute care telehealth, Oprah Winfrey backs Maven Clinic's $110 million round, a startup that developed a voice vital sign to quantify depression banked $26 million and other funding news in August. read more Resources Sponsored by: Patheon by Thermo Fisher Scientific Choose the right AAV platform for your viral vector-based therapy Sponsored by: XIFIN inc. Download the Value of Precision Medicine Informatics (PMI) Initiatives report to learn about the technology, data types, and the value derived from more than 100 PMI initiatives. Sponsored by: EVERSANA Today’s economics do not allow manufactures to keep making decisions in an antiquated way. They need to challenge tradition & deliver faster, cheaper, successful launches. Learn how. Sponsored by: Thermo Fisher Scientific Thermo Fisher Scientific introduces a new NK cell culture medium designed to support feeder-free, high-yield growth for cell therapy applications. Sponsored by: Cascade Chemistry by Aceto Read four customer success stories and four success factors that helped move pharmaceutical customers of Cascade Chemistry by Aceto quickly and effectively to clinic with trial-ready APIs. Sponsored by: ConnectiveRx Topple barriers to getting patients started on therapy. Guide them with mobile. Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. | 
